
State:
Not Disclosed
Category:
Pharmaceuticals & Supplements
Asking Price:
-
Revenue:
-

Asset Overview
PRIME exits and American Healthcare Capital are pleased to exclusively present a Phase I-ready biopharmaceutical asset with significant potential in multiple high-growth therapeutic areas. Developed by an experienced team, this bifunctional peptide therapy addresses critical unmet needs in orphan indications such as pulmonary arterial hypertension (PAH) and sarcoidosis, with expansion opportunities into broader markets like chronic obstructive pulmonary disease (COPD) with cachexia, congestive heart failure (CHF) with cachexia, oncology, HIV-associated lipodystrophy, mild cognitive impairment (MCI) and MASH.
This therapy’s innovative mechanism of action combines growth hormone-releasing factor (GRF) and vasoactive intestinal peptide (VIP) properties, delivering anti-inflammatory, cardioprotective, pneumoprotective, lipolytic and anabolic benefits. Both peptides have been validated in clinical setting in cardio-pulmonary indications.
The asset is protected by patents in over 30 countries, including the U.S. and EU, and is primed for clinical development with Canadian IND approval secured. The IP expires in 2037 and can be extended.
Manufacturing processes for the asset are simple and highly scalable, with low costs of goods, ensuring strong margins.
The asset’s strong market potential is bolstered by opportunities to capture value in orphan indications and broader therapeutic areas with significant patient populations and high unmet needs, which can be developed in sequence to significantly reduce the clinical risk.
This opportunity is ideal for strategic or financial buyers seeking to add a first-in-class therapy to their pipeline. The seller is open to various transaction structures, including licensing, co-development, or acquisition.
Asking Price
The asking price for this opportunity is to be determined, and all competitive offers will be considered.
Inquire About This Listing:
In order to learn more about our listing, you must: